Overview

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

Status:
Terminated
Trial end date:
2009-09-29
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-371797 (versus placebo) in treating ankylosing spondylitis, and to further evaluate the drug's safety. Approximately 130 patients from the US, Canada, Poland and Hungary will be enrolled in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Array BioPharma
Pfizer